Carcinoid heart disease

Area of Science:

• Cardiology
• Oncology
• Biochemistry

Background:

• Carcinoid syndrome, often from liver metastasis of neuroendocrine tumors, affects 40% of patients with carcinoid heart disease (CHD).
• Serotonin (5-HT) is implicated in the fibrotic process leading to CHD, primarily affecting right-sided heart valves (tricuspid and pulmonary).
• Left-sided valvular involvement and coronary vasospasm occur in a minority of CHD patients.

Purpose of the Study:

• To review the pathophysiology, diagnosis, and treatment of carcinoid heart disease.
• To analyze the impact of therapeutic advances on patient survival.
• To investigate the correlation between tumor markers and long-term survival in CHD.

Main Methods:

• Literature review of carcinoid syndrome and carcinoid heart disease.
• Analysis of echocardiographic findings in CHD.
• Review of therapeutic outcomes, including valve replacement and survival data.

Main Results:

• Echocardiography shows characteristic valve immobility, thickening, and retraction, leading to tricuspid regurgitation and pulmonary stenosis.
• Surgical mortality for valve replacement has decreased from >20% to <10% due to technical advances and earlier diagnosis.
• Median survival in CHD patients has increased from 1.5 to 4.4 years over two decades, potentially due to multimodal treatment approaches.

Conclusions:

• Carcinoid heart disease requires specific diagnostic and therapeutic strategies, with valve replacement becoming more feasible.
• While overall survival has improved, a definitive correlation between reduced tumor markers and enhanced long-term survival in CHD remains to be rigorously established.